Corat Therapeutics

Corat Therapeutics is a private, preclinical/clinical-stage biotech developing fully human monoclonal antibodies for COVID-19. Its lead candidate, COR-101, demonstrated potent virus neutralization in preclinical models and entered clinical trials within a record 11 months of project initiation. The company positions its antibodies as a passive vaccine for immediate protection or treatment, targeting unmet needs in patient populations inadequately served by active vaccines. While currently focused on SARS-CoV-2, its antibody discovery platform could potentially be applied to other infectious diseases.

Antibody phage display using fully human antibody gene libraries derived from healthy and convalescent donors for the rapid identification and development of neutralizing monoclonal antibodies.

The market for SARS-CoV-2 neutralizing antibodies is competitive, with several products from major players like Regeneron, Eli Lilly, and AstraZeneca already authorized. Corat must differentiate based on efficacy against variants, safety of its fully human construct, or convenience of administration to capture market share.